Epidemiology of AIDS-Defining Malignancies
Living reference work entry
AIDS-defining malignancies are a subset of HIV-associated malignancies that include Kaposi sarcoma, some forms of non-Hodgkin lymphoma, and invasive cervical cancer. KS along with PCP are among the first diseases that comprised the original definition of AIDS “in the United States.” Subsequently, non-Hodgkin lymphoma (1985) and invasive cervical cancer were added (CDC 1992). Compared to non-AIDS-defining malignancies, Kaposi sarcoma and non-Hodgkin lymphoma demonstrated the highest incidence in the early AIDS epidemic (see “ History of the AIDS Epidemic”). As shown in Fig. 1, with the introduction of highly active antiretroviral therapy (HAART) in 1996, the incidence patterns of these cancers with the exception of cervical cancer dropped significantly. It is hypothesized that HAART restores immune function and delays progression to AIDS. However, even with the improved clinical outcome, HAART has not eliminated the risk of AIDS-defining malignancies. HIV-positive persons...
KeywordsCervical Cancer Immune Reconstitution Inflammatory Syndrome Invasive Cervical Cancer Primary Effusion Lymphoma Multicenter AIDS Cohort Study
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
- Breen EC, Hussain SK, Magpantay L, Jacobson LP, Detels R, Rabkin CS, Kaslow RA, Variakojis D, Bream JH, Rinaldo CR, Ambinder RF, Martinez-Maza O. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1303–14.PubMedCrossRefPubMedCentralGoogle Scholar
- Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1–19.Google Scholar
- Clarke MA, Wentzensen N, Mirabello L, Ghosh A, Wacholder S, Harari A, Lorincz AT, Schiffman M, Burk RD. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol Biomarkers Prev. 2012;21(12):2125–37.Google Scholar
- Franceschi S, Dal Maso L, Rickenbach M, Polesel J, Hirschel B, Cavassini M, Bordoni A, Elzi L, Ess S, Jundt G, Mueller N, Clifford GM, and the Swiss HIV Cohort Study. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer. 2008;99:800–4.PubMedCrossRefPubMedCentralGoogle Scholar
- Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, Bouchardy C, Dehler S, Jundt G, Ess S, Bordoni A, Konzelmann I, Frick H, Dal Maso L, Elzi L, Furrer H, Calmy A, Cavassini M, Ledergerber B, Keiser O, and the Swiss HIV Cohort Study. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer. 2010;103:416–22.PubMedCrossRefPubMedCentralGoogle Scholar
- Hamilton-Dutoit SJ, Pallesen G, Franzmann MB, Karkov J, Black F, Skinhoj P, Pedersen C. AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am J Pathol. 1991;138(1):149–63.PubMedPubMedCentralGoogle Scholar
- Polesel J, Clifford GM, Rickenbach M, Dal Maso L, Battegay M, Bouchardy C, Furrer H, Hasse B, Levi F, Probst-Hensch NM, Schmid P, Franceschi S, and the Swiss HIV Cohort Study. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS. 2008;22:301–6.PubMedCrossRefGoogle Scholar
- Spagnuolo V, Galli L, Salpietro S, Gianotti N, Guffanti M, Cossarini F, Bigoloni A, Cinque P, Bossolasco S, Travi G, Fumagalli L, Lazzarin A, Castagna A. Ten-year survival among HIV-1 infected subjects with AIDS or non-AIDS-defining malignancies. Int J Cancer. 2012;130:2990–6.PubMedCrossRefGoogle Scholar
© Springer Science+Business Media New York 2013